Emmaus Life Sciences, Inc. (EMMA) Form 8-K — May 15, 2026
Emmaus Life Sciences reported Q1 2026 net revenues of $2.0 million, an 18% decline year-over-year, driven by a 33% drop in U.S. sales due to generic L-Glutamine competition. This decline was partially offset by a 446% surge in sales in the Middle East and North Africa region. The company posted a net loss of $3.3 million ($0.05 per share), widening from $2.3 million in the prior year, primarily due to increased interest expense and fair value changes in derivatives.
Key figures
- Revenue
- 1982000
- Total Debt
- 86556000
- Cash Position
- 1072000
- Operating Expenses
- 2637000
- Current Liabilities
- 70537000
- Weighted Average Shares
- 70188263
Price after filing
Close on the filing date to close N calendar days later (from $0.01). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.